Xu T

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.

Xu T, Schulga A, Konovalova E, ..., Tolmachev V, Vorobyeva A

Int J Mol Sci 24 (3) - [2023-02-02; online 2023-02-02]

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy.

Yin W, Xu T, Altai M, ..., Gräslund T, Orlova A

Pharmaceutics 13 (11) - [2021-11-21; online 2021-11-21]

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.

Xu T, Vorobyeva A, Schulga A, ..., Tolmachev V, Deyev SM

Cancers (Basel) 13 (16) - [2021-08-04; online 2021-08-04]

Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1.

Deyev SM, Xu T, Liu Y, ..., Tolmachev V, Vorobyeva A

Cancers (Basel) 13 (14) - [2021-07-17; online 2021-07-17]

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.

Vorobyeva A, Konovalova E, Xu T, ..., Tolmachev V, Deyev S

Int J Mol Sci 21 (9) - [2020-05-07; online 2020-05-07]